CAR T-cell therapy NXC-201 given orphan drug status in EU
NXC-201, an investigational CAR T-cell therapy, has been designated…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreNXC-201, an investigational CAR T-cell therapy, has been designated…
At its 15th annual gala, held in New York…
A unanimous vote by a committee of the U.S.
The U.S. Food and Drug Administration (FDA) has approved…
The U.S. Food and Drug Administration (FDA) has expanded…
Combining the cancer therapy Venclexta (venetoclax) with a molecule…